                         SEQUENCE LISTING

<110>  IMMUNOVACCINE TECHNOLOGIES INC.
 
<120>  Methods of Using Low Dose Volume B-cell Epitope Compositions for 
       Inducing an Antibody Immune Response in Human Subjects

<130>  78961-181

<140>  PCT/CA2016/xxxxxx
<141>  2016-09-27

<160>  12    

<170>  PatentIn version 3.5

<210>  1
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  RSV SHe A peptide

<400>  1

Asn Lys Leu Cys Glu Tyr Asn Val Phe His Asn Lys Thr Phe Glu Leu 
1               5                   10                  15      


Pro Arg Ala Arg Val Asn Thr 
            20              


<210>  2
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  RSV SHe B peptide

<400>  2

Asn Lys Leu Ser Glu His Lys Thr Phe Cys Asn Lys Thr Leu Glu Gln 
1               5                   10                  15      


Gly Gln Met Tyr Gln Ile Asn Thr 
            20                  


<210>  3
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Palmitic Acid Adjuvant


<220>
<221>  Misc_Feature
<222>  (1)..(1)
<223>  Linked to PAM2 or PAM3

<400>  3

Cys Ser Lys Lys Lys Lys 
1               5       


<210>  4
<211>  64
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human RSV SH Subgroup A

<400>  4

Met Glu Asn Thr Ser Ile Thr Ile Glu Phe Ser Ser Lys Phe Trp Pro 
1               5                   10                  15      


Tyr Phe Thr Leu Ile His Met Ile Thr Thr Ile Ile Ser Leu Leu Ile 
            20                  25                  30          


Ile Ile Ser Ile Met Ile Ala Ile Leu Asn Lys Leu Cys Glu Tyr Asn 
        35                  40                  45              


Val Phe His Asn Lys Thr Phe Glu Leu Pro Arg Ala Arg Val Asn Thr 
    50                  55                  60                  


<210>  5
<211>  65
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human RSV SH Subgroup B

<400>  5

Met Gly Asn Thr Ser Ile Thr Ile Glu Phe Thr Ser Lys Phe Trp Pro 
1               5                   10                  15      


Tyr Phe Thr Leu Ile His Met Ile Leu Thr Leu Ile Ser Leu Leu Ile 
            20                  25                  30          


Ile Ile Thr Ile Met Ile Ala Ile Leu Asn Lys Leu Ser Glu His Lys 
        35                  40                  45              


Thr Phe Cys Asn Lys Thr Leu Glu Gln Gly Gln Met Tyr Gln Ile Asn 
    50                  55                  60                  


Thr 
65  


<210>  6
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  RSV SHe A peptide variant

<400>  6

Asn Lys Leu Ser Glu Tyr Asn Val Phe His Asn Lys Thr Phe Glu Leu 
1               5                   10                  15      


Pro Arg Ala Arg Val Asn Thr 
            20              


<210>  7
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HPV R9F peptide

<400>  7

Arg Ala His Tyr Asn Ile Val Thr Phe 
1               5                   


<210>  8
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CpG Oligonucleotide

<400>  8
tccatgacgt tcctgacgtt                                                   20


<210>  9
<211>  26
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PolyI:C polynucleotide


<220>
<221>  modified_base
<222>  (1)..(1)
<223>  Inosine

<220>
<221>  modified_base
<222>  (3)..(3)
<223>  Inosine

<220>
<221>  modified_base
<222>  (5)..(5)
<223>  Inosine

<220>
<221>  modified_base
<222>  (7)..(7)
<223>  Inosine

<220>
<221>  modified_base
<222>  (9)..(9)
<223>  Inosine

<220>
<221>  modified_base
<222>  (11)..(11)
<223>  Inosine

<220>
<221>  modified_base
<222>  (13)..(13)
<223>  Inosine

<220>
<221>  modified_base
<222>  (15)..(15)
<223>  Inosine

<220>
<221>  modified_base
<222>  (17)..(17)
<223>  Inosine

<220>
<221>  modified_base
<222>  (19)..(19)
<223>  Inosine

<220>
<221>  modified_base
<222>  (21)..(21)
<223>  Inosine

<220>
<221>  modified_base
<222>  (23)..(23)
<223>  Inosine

<220>
<221>  modified_base
<222>  (25)..(25)
<223>  Inosine


<400>  9
ncncncncnc ncncncncnc ncncnc                                            26


<210>  10
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tetanus toxin peptide A16L

<400>  10

Ala Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu 
1               5                   10                  15      


<210>  11
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  T-helper epitope PADRE


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa may be cyclohexylalanyl

<400>  11

Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala 
1               5                   10              


<210>  12
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tetanus toxoid peptide F21E

<400>  12

Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser 
1               5                   10                  15      


Ala Ser His Leu Glu 
            20      


